SK Capital Partners has announced that it, Eurazeo and other shareholders in Seqens have entered a formal agreement for it to acquire Seqens. This follows a period of exclusive negotiations and the agreement of the employee representative body. This remains subject to regulatory approval. S

Eurazeo has announced that it has entered into exclusive discussions to sell its stake in French-based CDMO Seqens to funds advised by SK Capital Partners and its existing French shareholders, Mérieux Equity Partners.

Seqens commented that SK Capital’s involvement could enhance its position in the production of APIs, pharmaceutical intermediates and speciality ingredients. SK has already owned API manufacturer Wavelength Pharmaceuticals since 2017.

Clariant has agreed to sell 80% of its Pigments business to a consortium made up of German pigments specialist Heubach Group and private investment firm SK Capital Partners, which owns many other chemical industry operations. This should close in 1H 2022.

New York-based SK Capital Partners has acquired most of Huntsman’s stake in TiO₂ pigments and performance additives producer Venator Materials, which Huntsman span off in 2017. In all, it has bought a 40% stake or 42.5 million shares for about $100 million, including a 30-month option to buy the remaining 9.5 million at $2.15/share.